Indications: Prophylaxis of Mycobacterium avium complex infections in immunosuppressed patients with low CD4 count. Treatment of non-tuberculous mycobacterial disease, in combination with other drugs. Treatment of pulmonary tuberculosis, in combination with other drugs. CHILD not recommended.

Cautions: acute porphyria.

Contra-indications: rifamycin hypersensitivity.

Hepatic impairment : reduce dose in severe impairment Renal impairment : use half normal dose if eGFR less than 30 ml/minute/1.73 m2.

Pregnancy : manufacturer advises avoid since no information available.

Breast-feeding: manufacturer advises avoid since no information available.

Side Effects: nausea, pyrexia, blood disorders (including leucopenia, anaemia, thrombocytopenia, and rarely haemolysis), myalgia, rash. less commonly vomiting, raised liver enzymes, jaundice, arthralgia, corneal deposits, uveitis especially following high doses or concomitant use with drugs that increase plasma concentration, hypersensitivity reactions (including eosinophilia, bronchospasm), skin, urine, saliva and other body secretions coloured orange-red; also reported hepatitis, influenza-like symptoms, chest pain, dyspnea Dose: Prophylaxis of Mycobacterium avium complex infections in immunosuppressed patients with low CD4 count: 300 mg daily as a single dose.

Treatment of non-tuberculous mycobacterial disease (in combination with other drugs): 450–600 mg daily as a single dose for up to 6 months after cultures negative Treatment of pulmonary tuberculosis (in combination with other drugs): 150–450 mg daily as a single dose for at least 6 months.